Table 3 Univariable comparisons of clinical characteristics in patients with hypotension according to the vasopressor tapered immediately before developing hypotension
Variables | Hypotension on tapering of AVP (n = 12) | Hypotension on tapering of NE (n = 46) | P value |
|---|---|---|---|
Age | 67 (59 – 69) | 65 (56 – 73) | 0.773 |
Gender, male | 10 (83.3) | 30 (65.2) | 0.307 |
Causes of septic shocka | 0.246 | ||
Pneumonia | 8 (66.7) | 20 (43.5) | |
Intraabdominal infection | 2 (16.7) | 14 (30.4) | |
Urogenital infection | 3 (25.0) | 6 (13.0) | |
Cather related infection | 0 (0.0) | 4 (8.7) | |
Endocarditis | 0 (0.0) | 2 (4.3) | |
Othersb | 0 (0.0) | 3 (6.5) | |
MAP before initial resuscitation, mmHg | 53 (47 – 57) | 51 (42 – 57) | 0.214 |
CVP before initial resuscitation, mmHg | 7 (3 – 10) | 6 (6 – 8) | 0.161 |
MAP at the time of vasopressor initiated, mmHg | 55 (47 – 57) | 55 (52 – 60) | 0.612 |
CVP at the time of vasopressor initiated, mmHg | 11 (10 – 13) | 11 (8 – 14) | 0.669 |
Total bilirubin, mg/dL | 0.90 (0.35 – 3.05) | 1.20 (0.50 – 2.70) | 0.382 |
Serum creatinine, mg/dL | 1.47 (0.71 – 2.01) | 1.42 (0.97 – 2.32) | 0.687 |
Lactic acid, mmol/L (n = 57) | 3.27 (1.91 – 4.62) | 4.31 (2.67 – 6.32) | 0.229 |
Procalcitonin, ng/mL (n = 53) | 13.09 (4.18 – 81.53) | 11.01 (2.61 – 30.97) | 0.602 |
C-reactive protein, mg/mL | 14.87 (8.51 – 29.72) | 12.57 (5.59 – 19.42) | 0.129 |
Maximum NE dose during study period, ug/kg/min | 0.74 (0.54 – 1.56) | 0.70 (0.46 – 1.20) | 0.448 |
SAPS3 | 74 (62 – 86) | 73 (62 – 84) | 0.931 |
SOFA | 9 (8 – 13) | 10 (8 – 12) | 0.601 |
Clinical status on randomization | |||
MAP, mmHg | 72 (70 – 78) | 77 (73 – 81) | 0.138 |
CVP, mmHg | 10 (8 – 12) | 10 (8 – 14) | 0.420 |
Need for mechanical ventilation | 10 (83.3) | 31 (67.4) | 0.478 |
Need for renal replacement therapy | 4 (33.3) | 14 (30.4) | 1.000 |
Need for dobutamine | 1 (8.3) | 3 (6.5) | 1.000 |
SOFA | 13(11 – 16) | 12 (9 – 15) | 0.255 |
PF ratio | 118.8 (81.9 – 177.9) | 186.9 (105.4 – 278.0) | 0.110 |
Total bilirubin, mg/dL | 1.35 (0.53 – 3.68) | 1.40 (0.80 – 3.88) | 0.744 |
Serum creatinine, mg/dL | 1.25 (0.60 – 1.99) | 1.26 (0.81 – 2.21) | 0.508 |
Corticosteroid treatment | 10 (90.9) | 42 (95.5) | 0.495 |
Copeptin, pg/mL (n = 56) | 77 (67 – 90) | 168 (131 – 207) | < 0.001 |
Time to randomization, hours | 25.1 (14.1 – 41.8) | 21.1 (11.8 – 46.2) | 0.818 |
Time to discontinuation of vasopressors just before hypotension developed | 28.8 (18.5-44.3) | 22.0 (13.6-47.2) | 0.946 |
Time to hypotension after discontinuation of vasopressor, hours | 2.5 (1.1 – 3.3) | 2.5 (1.9 – 4.7) | 0.442 |
MAP at the time of hypotension developed on tapering of vasopressor, mmHg | 61 (57 – 63) | 62 (59 – 63) | 0.214 |
CVP at the time of hypotension developed on tapering of vasopressor, mmHg | 10 (6 – 12) | 10 (7 – 14) | 0.735 |
Total vasopressor duration, hours | 63.4 (38.9 – 122.6) | 57.8 (38.9 – 88.0) | 0.578 |
Clinical outcomes | |||
ICU mortality | 5 (41.7) | 13 (28.3) | 0.486 |
ICU length of stay, days | 12 (8 – 22) | 8 (3 – 12) | 0.108 |
28-day mortality | 5 (41.7) | 17 (37.8) | 1.000 |
Hospital mortality | 6 (50.0) | 20 (46.5) | 0.686 |
Hospital stay, days | 27 (19 – 30) | 22 (14 – 39) | 0.617 |